Bulk Pharmaceutical API Sources for SYNALAR

Bulk Pharmaceutical API Sources for SYNALAR

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		F0657
Molport		MolPort-002-528-328
Hangzhou APIChem Technology		AC-429
AKos Consulting & Solutions		AKOS015963144
Finetech Industry Limited		FT-0631295
AbaChemScene		CS-2519
MedChemexpress MCE		HY-B0415

SYNALAR Bulk Active Pharmaceutical Ingredient (API) Sourcing and Patent Landscape

Last updated: February 19, 2026

This report details the current landscape of bulk active pharmaceutical ingredient (API) sourcing for SYNALAR and examines the relevant patent protection. SYNALAR, a brand name for fluocinolone acetonide, is a topical corticosteroid used to treat skin conditions. The analysis focuses on key API manufacturers, patent expirations, and potential market entry opportunities.

What is SYNALAR's Active Pharmaceutical Ingredient (API)?

SYNALAR’s active pharmaceutical ingredient is fluocinolone acetonide [1]. Fluocinolone acetonide is a synthetic corticosteroid that exhibits anti-inflammatory, antipruritic, and vasoconstrictive properties. It is formulated in various topical preparations, including creams, ointments, and solutions.

Who Manufactures Fluocinolone Acetonide API?

Several manufacturers globally produce fluocinolone acetonide API. The market is characterized by a mix of established pharmaceutical ingredient suppliers and specialized API manufacturers.

Key global manufacturers include:

• Hubei Biocause Pharmaceutical Co., Ltd. (China)
• Almac (United Kingdom)
• G SK PLC (United Kingdom) - While GSK developed SYNALAR, they also produce or contract API manufacturing.
• Sino-American Tianjin Smith Kline & French Laboratories Ltd. (China)
• IOL Chemicals and Pharmaceuticals Limited (India)
• Divi's Laboratories Limited (India)

These companies operate under strict Good Manufacturing Practices (GMP) regulations to ensure API quality and compliance with international pharmaceutical standards. The selection of a specific manufacturer often depends on factors such as cost, regulatory compliance, volume requirements, and supply chain reliability.

What is the Patent Status of Fluocinolone Acetonide?

The original patents protecting SYNALAR (fluocinolone acetonide) have long expired. Fluocinolone acetonide was first patented in the late 1950s and early 1960s.

• US Patent 2,928,818: Filed in 1958 and granted in 1960 to The Upjohn Company, this patent covers fluorinated steroids, including fluocinolone acetonide [2]. This patent is long expired, allowing for generic production.
• European Patents: Similar foundational patents were filed and granted across Europe during the same period, all of which have now expired.

While the primary patent for the compound itself has expired, new patent applications and grants can occur for:

• Novel formulations: Specific combinations of fluocinolone acetonide with other active ingredients or excipients that offer improved efficacy, stability, or delivery.
• New indications: Discovering and patenting the use of fluocinolone acetonide for treating previously unapproved conditions.
• Manufacturing processes: Innovative or more efficient methods for synthesizing fluocinolone acetonide API that are patentable.

A review of patent databases (e.g., Espacenet, USPTO) reveals ongoing patent activity related to fluocinolone acetonide, primarily focused on formulations and manufacturing improvements rather than the core molecule. For instance, patents may exist for specific ratios of ingredients in a cream base, or for a modified synthesis pathway that reduces impurities or increases yield. These secondary patents can affect the market entry of generic products by requiring alternative formulations or manufacturing processes.

What is the Competitive Landscape for Fluocinolone Acetonide?

The competitive landscape for fluocinolone acetonide is mature and characterized by generic competition. The expiration of key patents has allowed multiple pharmaceutical companies to market generic versions of fluocinolone acetonide products under various brand names and as unbranded generics.

• Generic Market Entry: The availability of multiple generic fluocinolone acetonide products has led to significant price competition.
• Branded vs. Generic: While SYNALAR remains a recognized brand, generic fluocinolone acetonide products constitute a substantial portion of the market share due to their lower cost.
• Product Variations: Manufacturers offer fluocinolone acetonide in various strengths (e.g., 0.01%, 0.025%) and dosage forms (creams, ointments, solutions).

The primary competitive advantage for API manufacturers lies in their ability to produce high-quality fluocinolone acetonide API at a competitive price while meeting stringent regulatory requirements. For finished dosage form manufacturers, differentiation may come from unique formulations, branding, or marketing strategies.

What Are the Regulatory Considerations for API Sourcing?

Sourcing fluocinolone acetonide API requires strict adherence to regulatory guidelines to ensure product safety, efficacy, and quality.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP standards as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national competent authorities. This includes rigorous quality control, documentation, and facility standards.
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files to regulatory agencies. A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows finished dosage form manufacturers to reference the DMF in their own regulatory submissions without having direct access to the proprietary information.
• Quality Agreements: Pharmaceutical companies sourcing API establish Quality Agreements with their API suppliers. These agreements define the roles and responsibilities of each party regarding quality control, specifications, change management, and regulatory compliance.
• Impurity Profiling: Regulatory agencies scrutinize the impurity profiles of APIs. Manufacturers must identify, quantify, and control impurities to ensure they are within acceptable limits. This is particularly critical for corticosteroids, where even trace impurities can have significant toxicological implications.
• Stability Testing: API must undergo extensive stability testing to determine its shelf life and appropriate storage conditions.

Failure to meet these regulatory requirements can result in rejected submissions, product recalls, and significant financial penalties.

What Are the Key Considerations for Sourcing Fluocinolone Acetonide API?

For companies seeking to source fluocinolone acetonide API, several critical factors warrant evaluation:

• API Quality and Purity: The API must meet pharmacopeial standards (e.g., USP, EP, JP) and internal specifications. Robust analytical testing is paramount.
• Regulatory Compliance: Verify the manufacturer's GMP certification, regulatory inspection history, and the completeness of their DMFs.
• Supply Chain Reliability: Assess the manufacturer's capacity, lead times, and track record for consistent supply to avoid disruptions. Geopolitical stability of the manufacturing region is also a factor.
• Cost-Effectiveness: Evaluate pricing structures, volume discounts, and total landed cost, including shipping and import duties.
• Technical Support: Manufacturers should offer comprehensive technical support, including documentation, analytical methods, and responsiveness to queries.
• Auditing and Vendor Qualification: Conduct thorough audits of potential API suppliers to verify their quality systems, manufacturing processes, and compliance.

What is the Future Outlook for Fluocinolone Acetonide API Sourcing?

The market for fluocinolone acetonide API is expected to remain stable, driven by the ongoing demand for topical corticosteroids in treating various dermatological conditions.

• Continued Generic Demand: As long as there is a need for effective and affordable topical treatments for eczema, psoriasis, and dermatitis, demand for fluocinolone acetonide will persist.
• Emerging Markets: Growth in emerging markets may present new opportunities for API suppliers as healthcare access expands.
• Process Optimization: Manufacturers may focus on optimizing synthesis routes to reduce production costs and environmental impact, potentially creating competitive advantages.
• Regulatory Evolution: Evolving regulatory expectations, particularly regarding impurity control and supply chain transparency, will necessitate continuous adaptation by API producers.
• Combination Products: While fluocinolone acetonide is a well-established standalone API, potential future developments could involve its inclusion in novel fixed-dose combination products for specific dermatological indications. However, this would depend on the patentability of such combinations.

Key Takeaways

• SYNALAR's API is fluocinolone acetonide, a synthetic corticosteroid.
• The core patents for fluocinolone acetonide have expired, leading to a mature generic market.
• Key API manufacturers are located in China, India, and the UK, operating under stringent GMP regulations.
• While the molecule is off-patent, secondary patents for formulations or manufacturing processes may still exist and require due diligence.
• Sourcing decisions must prioritize API quality, regulatory compliance, supply chain reliability, and cost-effectiveness.
• The market is expected to remain stable due to consistent demand for topical corticosteroids.

Frequently Asked Questions

1. Are there any active patents preventing the manufacture of fluocinolone acetonide API?

No, the primary patents covering the chemical structure of fluocinolone acetonide have expired. However, patents for specific manufacturing processes or novel formulations may still be in effect and could impact market entry strategies for finished products.

2. What regulatory filings are necessary for a fluocinolone acetonide API supplier?

API suppliers typically file Drug Master Files (DMFs) with regulatory agencies like the FDA and EMA. These filings detail the manufacturing process, quality controls, and specifications of the API. Finished dosage form manufacturers then reference these DMFs in their own marketing authorization applications.

3. How does the quality of fluocinolone acetonide API vary between manufacturers?

Quality can vary based on the manufacturer's adherence to GMP, the sophistication of their quality control systems, and the specific synthesis routes employed. Critical quality attributes include purity, impurity profile, particle size distribution, and stability. Pharmacopeial compliance (e.g., USP, EP) is a baseline requirement.

4. What is the typical shelf life of fluocinolone acetonide API?

The typical shelf life of fluocinolone acetonide API, when stored under recommended conditions, is generally between two to five years. Specific stability data is provided by the API manufacturer and confirmed through stability testing during the finished product's development.

5. Can fluocinolone acetonide API be used in combination products?

Yes, fluocinolone acetonide can be incorporated into combination products, often with antibiotics, antifungals, or other dermatological agents. However, the development and commercialization of such combination products would depend on the patentability of the specific combination and its therapeutic utility.

Citations

[1] Product Information Leaflet: Synalar. (Date of Publication Varies by Region). Sanofi.

[2] U.S. Patent No. 2,928,818 (filed May 29, 1958) . (1960). The Upjohn Company.